Make the most of your digital experience
Tailor Your Agenda – with sessions spanning across multiple days, design your own agenda based on who you want to hear from and what will be most useful to your business.
Get More Involved – virtual events offer many more interactive opportunities than live events; participate in live polls, live Q&A and live panel discussions – helping you build your personal brand and your business connections.
Improved Audience Visibility – you can see exactly who is registered to attend the event and when they’re online – make that valuable connection in real-time!
On-Demand Content – missed a session or couldn’t tune in that day? That’s fine, sessions will be available to listen to for 2 months post event. That also means you can listen to your favourite speaker multiple times.
High Quality Speakers – this doesn’t change, whether we run a live event or a virtual one, we recruit industry leading, insightful speakers to inspire.
More Networking Opportunities – do you sometimes miss the one person you were hoping to meet at live events? With virtual events you can instant message them, reserve a time in their diary, and email them.
Save Time & Money – tune into an event from the comfort of your own home, no need to travel overseas, spend time away from loved ones and spend your company’s money! This makes networking and knowledge sharing much more cost efficient.
Increased Content – we can run more sessions at one time without the constraints of venue capacities, meaning we can provide you with more valuable content in one go.
Business Development Opportunities – for those looking to partner on the virtual events, there’s lots of session formats that will place you at the centre of the conversations you need to have, including but not limited to; topic specific roundtables, keynote panels, ask the expert chat rooms and more. Talk to our team to find out more [email protected].
Insights – using analytics, we can help you benchmark, to stay ahead of industry trends. We can also share audience insights on job titles, seniority and geography, so you know your networking with the right connections to match your business needs.
Why Attend
The gut microbiome is becoming an increasingly important druggable target for pharma companies through a range of modalities from FMT to small molecule and even phage. 2020 looks set to be a pivotal year for the microbiome industry with a handful of companies (including Seres, Rebiotix and Finch Therapeutics) set to release ground-breaking phase 3 clinical data. We’re a step away from market approval, but there’s still so much to learn…
Major advances in shotgun metagenomic sequencing and computational biology allow us to see what’s going on at a strain-specific and metabolomic level of detail. Elucidating the key metabolites and mechanisms of action in both extra-intestinal and intestinal indications is a key objective in 2020/2021 and is a cornerstone of the discussion at Microbiome Connect: Human.
Join key opinion leaders to examine the latest preclinical and clinical data in extra-intestinal and intestinal indications. This is your opportunity to translate gut-microbiome research into therapeutics that have the power to treat oncological, neurological, gastro-intestinal & metabolic diseases.
Previously known as North American Microbiome Congress, Microbiome Connect: Human USA is all about connecting leading academics and biotech companies presenting preclinical and clinical data, to network, educate and share knowledge.
What's new for 2020
- Deep dive into the microbiome’s mechanistic and metabolomic role in Neurological, Oncological, Gastro-Intestinal & Metabolic indications with three distinct scientific streams of the latest pre-clinical and clinical data.
- Assess how leading biotech companies and academics are designing a range of therapeutic microbiome-modulating modalities from small-molecule and Phage to rationally designed live bio-therapeutics and FMT.
- Meet your next commercial partner and learn exactly what Pharma and VCs are looking for in terms of pre-clinical and clinical data to finance academic spin-outs and later-stage clinical trials.
Speakers
Johan van Hylckama Vlieg
Johan E.T. van Hylckama Vlieg is currently Senior Director Microbiome at Chr. Hansen AS, one of the largest microbe producing companies in the world. He is responsible for the microbiome innovation program and heading the microbiome research and pilot facility. He has 20 years of experience and leadership in gut microbiology, probiotics and food biotechnology in industry and academia. He is (co)author of more than 70 peer-reviewed publications and inventor of 13 patents or patent applications.
Dan Couto
Jessica Schneider
Christopher Missling
Christopher U. Missling, PhD is President and CEO of Anavex Life Sciences Corp and has over 20 years of healthcare industry experience within large pharmaceutical companies and the biotech industry. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Christopher’s work was dedicated to finding potential cures for neurodegenerative and neurodevelopmental diseases, like Alzheimer’s disease, and Parkinson’s disease, as well as Rett syndrome, Fragile X, Angelman’s syndrome, infantile spasms. Dr. Missling is working with his team to advance new potential treatments through clinical trials by involving the respective advocacy groups early on. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management and WHU Otto Beisheim School of Management.
Julius Goepp
Assaf Oron
Frank Middleton
Grégory Lambert
Grégory Lambert’s career has been split between biotech and pharma as VP of R&D and CSO in companies such as Novagali Pharma (now Santen) and Septodont. His responsibilities have included innovation, CMC, pre-clinical and clinical development in both Europe and North America. Grégory also has experience managing IP, business development and general management. He is an inventor on more than 20 patents, he was involved in the IPO of Novagali Pharma and he has driven the development of several pharmaceutical products from the laboratory through to market authorisation. In 2014, Gregory joined the scientific founders of TargEDys as CEO to setup the business plan and start operations, so far has raised over 10M€ in a mixture of grant and VC funding and begins human clinical trials this year.
Serguei Fetissov
Dan Couto
Mike Romanos
Mike Romanos is a co-founder and Chief Executive of Microbiotica. He has 30 years’ experience in the biotech and pharma industry and previously co-founded Crescendo Biologics which he built and led as CEO and CSO, developing a leading antibody fragment discovery platform and pipeline in oncology and inflammation. Prior to that he held global VP roles in GlaxoSmithKline R&D over 10 years, during which time he formed and led major transnational divisions which helped shape the company’s discovery platforms and pipelines across therapeutic areas and modalities. In his last role he led a transnational group of 300 staff providing genomics, target and biomarker discovery, and platform biology for R&D. Mike is highly experienced in biotech translation and commercialisation, currently serving as a Non-Exec Director of the life-sciences charity LifeArc, and previously as Translational Adviser in Biomedicine at Imperial College, Venture Partner to UK Innovation and Science Seed Fund, and committee member on the MRC’s Developmental Pathway Funding Scheme for translational academic research. Mike holds a degree in Natural Sciences from Cambridge University, a PhD in Molecular Virology from Imperial College, and is a Fellow of the Royal Society of Biology.
Bharat Dixit
Lucy Yanckello
Imke Mulder
Mingyang Song
Fyza Shaikh
Isabelle De Cremoux
Nicole McKnight
Diwakar Davar
Romain Dailiere
Nikole Kimes
Talk to me about… your research
Our mission at Siolta Therapeutics is to transform the therapeutic landscape of inflammatory diseases, such as asthma, through the power of the microbiome. As the lead executive driving Siolta’s early-stage development, I head a talented team of scientists, blending microbiology, immunology, and bioinformatics expertise to leverage microbiome data for the improvement of patient stratification and development of targeted microbial therapeutics. We are developing FDA-approved live biotherapeutics, as well as companion diagnostics, aimed not only at treating disease but also preventing disease, starting with asthma.
Talk to me about…something people may not know about you
My two professional passions have always been environmental systems and health. I have spent the entirety of my career exploring the relationship between these two concepts, from my time in the Solomon Islands as a Peace Corps Volunteer to my PhD work in marine ecosystems impacted by environmental alterations.
Heidi Hau
Morten Isaksen
Christopher Weidenmaier
Greg Perry
Sarah Garant
Laurent Chesnel
Qun Wang
Peter Nara
Dr. Nara is currently on of the co-founders, the Chief Scientific Officer and President Business Development for Keystone Bio Inc. in St. Louis, Mo., a Systemic-Oral Health Biomedical company that is targeting precision microbiome bio-therapeutics for the elimination of a specific oral bacterial associated with systemic inflammation. He is also the former co-founder, President, Chairman and CEO (1997-2017)and now Chairman Emeritus at Biological Mimetics, Inc. and cofounder of Lantern Pharma Inc. He holds a M.Sc. in Immuno-pharmacology, a combined Doctor of Veterinary Medicine and Ph.D. (retro-virology/oncogenesis) from The Ohio State University, 4 year combined residency in Comparative Pathology and NIH post-doctoral Fellowship at the Armed Forces Institute of Pathology and a NIH respectively. Dr. Nara currently holds the Endowed Eugene Lloyd Chair, Professor in Vaccinology, founding Center Director for the Center for Advanced Host Defense, Immunobiotics, and Translational Comparative Medicine in the Department of Biomedical Sciences, in the College of Veterinary Medicine at Iowa State University and also the Chief Executive Officer, President, Chairman & co-founder of Biological Mimetics, Inc.,. He is also an distinguished Alumni of The Ohio State University College of Veterinary Medicine 2014, and an elected Fellow of the American Association for the Advancement of Science in 2011. His comparative medical research interests are to more fully understand how early and pre-determined events in the host innate and acquired immune systems are sculpted and bias the development of protective long lasting responses against infectious pathogens and cancer. More importantly he and his team are interested developing new technologies and strategies to circumvent the non-protective immune responses for the development of novel classes of immunobiotics and vaccines focused on the prevention of disease and are translating these into viably products via a new academic- private-commercial model. He has been and continues as National and International member of numerous programs at the National Academy of Science, Institutes of Medicine, National Institutes of Health, Department of Defense, and Centers for Disease Control AIDS, World Health Organization, United Nations Global AIDS Characterization program–related and infectious diseases national planning, human and animal agricultural biodefense, vaccine development & policy reporting meetings involving pathogenesis, vaccine discovery, standardization, correlates of protection committees and consults and serves on numerous scientific advisory boards of corporate, private foundations and academic initiatives in the area of national biodefense, comparative medicine and immunology, vaccine discovery and immuno-therapeutics and a recent member of the U.S. State Department Bio-Industry Initiative Program, The Civilian Research and Development Foundation (CDRF) and The International Science and Technology Center (ISTC) for non-proliferation of biological agents.
Thought Leadership Partner
LabSkin
Website: https://www.labskin.co.uk/
Labskin’s pioneering approach to testing skin care products by cloning a patient’s skin microbiome and transplanting it on to Labskin human skin equivalent allows a wide range of testing that no longer requires invasive procedures on patients. Data from next generation sequencing of the Labskin and skin biome is coupled with AI processes to interpret and direct further development of skincare products in a controlled and efficient manner, reducing development time and costs.
Event Partners
Biose Industrie
Website: https://www.biose.com/en/cdmo/
Biose Industrie is a Contract Development and Manufacturing Organization (CDMO), specialised in Live Biotherapeutic Products. Founded in 1951, Biose Industrie has more than 65 years of experience in the development and production of live bacteria based drugs. Company offers lab development specialised in microbiology (anaerobic, aerobic, GMO strains) and is Drug GMP certified for the manufacturing of API (From 300L to 3 500L), clinical batches and commercial drug products (capsules in blisters or pills, sachets).
BioMe
Website: http://www.bio-me.no
Bio-Me AS is a Norwegian-based biotech company, and the culmination of 20 years research on best ways to detect various bacteria in communities. This research has led to novel, patented technologies and new approaches in bacterial analysis.
Leveraging on the vast information of gut bacteria and their function, Bio-Me's business model is built on three pillars of strength:
1. The proprietary GutCheck™
2. Unique access to 30,000+ fecal samples together with extensive patient information
3. A comprehensive database containing the output from 1 and 2 above, combined with sophisticated Machine Learning tools to discover novel connections between lifestyle, genetics and microbiome patterns.
This provides important insights to support Food and Pharma companies in creating better regimes for Personalized Nutrition and Precision Medicine, as well as offering other gut microbiome analysis services.
Eagle Genomics
Website: http://www.eaglegenomics.com
Eagle Genomics innovates at the intersection of biology, data science and bioinformatics to enable scientific decision making and to drive scientific discovery in the fields of microbiomics and human genomics.
Eagle Genomics knowledge discovery platform, e[automateddataascientist], transforms data into actionable insights that drive scientific decision making. The insight gained enables quick assessment of product potential, accelerates market entry and mitigates risk. Customers use our platform, powered by life sciences data, to prove the viability, efficacy and safety of products.
Media Partner
Rapid Microbiology
Website: https://www.rapidmicrobiology.com/
Rapidmicrobiology.com is a well-established online resource for microbiologists worldwide, find the right products for your microbiology lab using our specially designed search functions.
To keep up-to-date with the latest microbiology news get our free weekly newsletter which includes updates on products, services, webinars, training courses and conferences.
Microbiome Therapeutic Innovation Group
Website: https://microbiometig.org/
The Microbiome Therapeutics Innovation Group (MTIG) is an independent 501(c)(6) coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs. The human microbiome is one of the new frontiers of medical innovation that has the potential to benefit patients suffering from numerous diseases afflicting millions of patients and consuming billions of dollars of healthcare resources. Through a collective voice, the MTIG membership works together to enhance the regulatory, investment, and commercial environment to accelerate microbiome therapeutic product development and expand availability of life-changing and life-saving FDA approved microbiome therapies to patients. MTIG is committed to working with stakeholders who share in our mission and seek to collaborate with patients, patient advocates, professional societies/organizations/public health officials, scientists, government policymakers, healthcare providers and payers who seek tangible policy and regulatory solutions to issues in the emerging microbiome arena.
Become a Sponsor
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
FAO Attendees
For all confirmed attendees, you can access the final agenda on the Virtual event platform. If you haven’t yet received your login welcome email, please contact Guy Clayton [email protected]
Agenda
Fill in your details to download our full agenda which showcases the speakers as well as key topics we will be covering in Microbiome Connect: Human USA.
What you can expect from the 2020 Congress:
- 200+ Academic and Industry Leaders Onsite
- 50+ Thought Leaders on the Speaker Faculty
- 3 Distinct Streams
Download our Agenda
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
